Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia
Abstract Attention‐deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescri...
Main Authors: | Kentaro Kawabe, Fumie Horiuchi, Yu Matsumoto, Saori Inoue, Maya Okazawa, Rie Hosokawa, Kiwamu Nakachi, Junya Soga, Shu‐Ichi Ueno |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-03-01
|
Series: | Neuropsychopharmacology Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/npr2.12381 |
Similar Items
-
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis
by: Jain Rakesh, et al.
Published: (2011-11-01) -
Medications for attention‐deficit/hyperactivity disorder in Japan: A retrospective cohort study of label compliance
by: Daniel Fife, et al.
Published: (2021-09-01) -
Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
by: Joseph A, et al.
Published: (2016-03-01) -
Sleep Awareness of Japanese Outpatients: A Survey at a Psychiatry Department of a University Hospital
by: Junya Soga, et al.
Published: (2024-10-01) -
Rising prescription stimulant poisoning in Australia: a retrospective case series
by: Christopher Martin, et al.
Published: (2023-12-01)